Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
|Articles|August 2, 2016
- Pharmaceutical Technology-08-02-2016
- Volume 40
- Issue 8
Portable Pumping System for Continuous Inline Mixing
The Ross SysCon Portable Pumping System is capable of handling laminar and turbulent flow applications across a 26-element low pressure drop static mixer.
The Ross SysCon Portable Pumping System with Static Mixer from Ross, Charles & Son is capable of handling laminar and turbulent flow applications across a 26-element low pressure drop static mixer. The system is ideal for continuous inline mixing of minor liquid components into a fluid stream. The mixer produces a homogenous blend, despite differences in the viscosity and density of the materials being pumped. The mobile skid includes a variable frequency drive for the feed pump, inlet, and outlet pressure transmitters, 4-inch color touchscreen for viewing process variables, emergency stop button, and a vortex enclosure cooler for the NEMA 4 Operator Station.
Articles in this issue
about 10 years ago
Designing Flexible Aseptic Containment Systemsabout 10 years ago
Using 3D Printing for Solid-Dosage Drugsabout 10 years ago
One Strategy for Updating an Aging Facilityabout 10 years ago
Downstream Processing Continues to Worry CMOsabout 10 years ago
Quality Manufacturing Key to Stemming Drug Shortagesabout 10 years ago
New Equipment Meets Need for Innovation in Pharma Manufacturingabout 10 years ago
Evaluating Technology and Innovation in Biopharmaceutical Manufacturingabout 10 years ago
FDA and the Emerging Technology of 3D Printingabout 10 years ago
Measuring Equipment and Manufacturing Trendsabout 10 years ago
Manufacturing and Distribution Boundaries BlurRelated to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.